Drugdocs | Xadago

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Xadago

Chemical Name	safinamide
Dosage Form	Tablet (oral; 50, 100 mg)
Drug Class	Inhibitors
System	Musculoskeletal, Nervous
Company	US Worldmeds
Approval Year	2017

Indication

To treat Parkinson’s disease in conjunction with levodopa/carbidopa.

Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Xadago (Safinamide) Prescribing Information	2017	US WorldMeds, LLC, Louisville, KY

Document Title	Year	Source
Parkinson’s disease with motor fluctuations: safinamide.	2017	NICE

Document Title	Year	Source
A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.	2019	F1000Research
Comprehensive examination of therapies for pain in Parkinson’s disease: A systematic review and meta-analysis.	2018	Neuroepidemiology
A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.	2018	British Journal of Clinical Pharmacology